@article{e45d1404d653468f864986aecf37fef9,
title = "Brain structural and functional alterations in MOG antibody disease",
abstract = "BACKGROUND: The impact of myelin oligodendrocyte glycoprotein antibody disease (MOGAD) on brain structure and function is unknown.OBJECTIVES: The aim of this study was to study the multimodal brain MRI alterations in MOGAD and to investigate their clinical significance.METHODS: A total of 17 MOGAD, 20 aquaporin-4 antibody seropositive neuromyelitis optica spectrum disorders (AQP4 + NMOSD), and 28 healthy controls (HC) were prospectively recruited. Voxel-wise gray matter (GM) volume, fractional anisotropy (FA), mean diffusivity (MD), and degree centrality (DC) were compared between groups. Clinical associations and differential diagnosis were determined using partial correlation and stepwise logistic regression.RESULTS: In comparison with HC, MOGAD had GM atrophy in frontal and temporal lobe, insula, thalamus, and hippocampus, and WM fiber disruption in optic radiation and anterior/posterior corona radiata; DC decreased in cerebellum and increased in temporal lobe. Compared to AQP4 + NMOSD, MOGAD presented lower GM volume in postcentral gyrus and decreased DC in cerebellum. Hippocampus/parahippocampus atrophy associated with Expanded Disability Status Scale (R = -0.55, p = 0.04) and California Verbal Learning Test (R = 0.62, p = 0.031). The differentiation of MOGAD from AQP4 + NMOSD achieved an accuracy of 95% using FA in splenium of corpus callosum and DC in occipital gyrus.CONCLUSION: Distinct structural and functional alterations were identified in MOGAD. Hippocampus/parahippocampus atrophy associated with clinical disability and cognitive impairment.",
keywords = "Myelin oligodendrocyte glycoprotein associated disease, degree centrality, fractional anisotropy, gray matter volume, mean diffusivity, multimodal MRI",
author = "Zhizheng Zhuo and Yunyun Duan and Decai Tian and Xinli Wang and Chenyang Gao and Jinli Ding and Fenglian Zheng and Tian Zhang and Xinghu Zhang and Frederik Barkhof and Fu-Dong Shi and Yaou Liu",
note = "Funding Information: The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: F.B. is supported by the NIHR Biomedical Research Center at UCLH. This work was supported by the National Science Foundation of China (Nos. 81870958 and 81571631), the Beijing Municipal Natural Science Foundation for Distinguished Young Scholars (No. JQ20035), and the Special Fund of the Pediatric Medical Coordinated Development Center of Beijing Hospitals Authority (No. XTYB201831). Funding Information: The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Zhizheng Zhuo, Yunyun Duan, Decai Tian, Xinli Wang, Chenyang Gao, Jinli Ding, Fenglian Zheng, Tian Zhang, Xinghu Zhang, Fu-Dong Shi, and Yaou Liu declare that there is no conflict of interest. Professor Frederik Barkhof acts as a consultant for Bayer-Schering, Biogen-Idec, GeNeuro, Ixico, Merck-Serono, Novartis, and Roche. He has received grants, or grants are pending, from the Amyloid Imaging to Prevent Alzheimer{\textquoteright}s Disease (AMYPAD) initiative, the Biomedical Research Centre at University College London Hospitals, the Dutch MS Society, ECTRIMS–MAGNIMS, EU-H2020, the Dutch Research Council (NWO), the UK MS Society, and the National Institute for Health Research, University College London. He has received payments for the development of educational presentations from Ixico and to his institution from Biogen-Idec and Merck. He is on the editorial board of Radiology, Brain, European Radiology, Multiple Sclerosis Journal, and Neurology. Publisher Copyright: {\textcopyright} The Author(s), 2020.",
year = "2021",
month = aug,
doi = "https://doi.org/10.1177/1352458520964415",
language = "English",
volume = "27",
pages = "1350--1363",
journal = "MULTIPLE SCLEROSIS",
issn = "1352-4585",
publisher = "SAGE Publications Ltd",
number = "9",
}